Use of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients: Insights from a specialist atrial fibrillation clinic

International Journal of Clinical Practice

Volumn 69, Issue 11, 2015, Pages 1341-1348

  Lee, S I ^a,b   Sayers, M ^b   Lip, G Y H ^a,c   Lane, D A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANUS FISTULA; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; OUTCOME ASSESSMENT; POLYDIPSIA; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SLEEP DISORDER; TRANSIENT ISCHEMIC ATTACK; ADULT; CARDIOVASCULAR DISEASE; CLINICAL AUDIT; COMPLICATION; HEMORRHAGE; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CLINICAL AUDIT; DABIGATRAN; DRUG SUBSTITUTION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; STROKE; WARFARIN;

EID: 84946500614     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12712     Document Type: Article

References (22)

1. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
2. Camm AJ, Lip GY, De Caterina R, et al.,; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.
3. Shields AM, Lip GY,. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med 2015; 278 (1): 1-18.
4. National Institute for Health and Clinical Excellence (NICE). CG180 Atrial Fibrillation: The Management of Atrial Fibrillation. [Online] NICE 2014. http://www.nice.org.uk/guidance/cg180/chapter/1-recommendations#interventions-to-prevent-stroke-2 (accessed 29 March 2015).
5. Ruff CT, Giugliano RP, Braunwald E, et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.
6. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC,. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013; 19: e325-32.
7. Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA,. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015; 13: 495-504. doi: 10.1111/jth.12845.
8. Shore S, Ho PM, Lambert-Kerzner A, et al., Site-level variation in and practices associated with dabigatran adherence. JAMA 2015; 313: 1443-50.
9. Schulman S, Shortt B, Robinson M, Eikelboom JW,. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013; 11: 1295-9.
10. Zalesak M, Siu K, Francis K, et al., Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013; 6: 567-74.
11. Beyer-Westendorf J, Förster K, Ebertz F, et al., Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; 17: 530-8.
12. Lane DA, Aguinaga L, Blomström-Lundqvist C, et al., Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaciõn Cardíaca y Electrofisiología (SOLEACE). Europace 2015; June 24.pii:euv233. doi: 10.1093/europace/euv233 [Epub ahead of print]
13. National Institute for Health and Care Excellence (NICE). Patient Decision aid: Atrial Fibrillation: Medicines to Help Reduce Your Risk of a Stroke-What are the Options? [Online] NICE 2014. https://www.nice.org.uk/guidance/cg180/resources/cg180-atrial-fibrillation-update-patient-decision-aid2 (accessed 22 March 2015).
14. Clarkesmith DE, Pattison HM, Lip GYH, Lane DA,. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE 2013; 8: e74037.
15. Bristol-Myers Squibb. Assessment of an Education and Guidance Programme for Eliquis Adherence in non-Valvular Atrial Fibrillation (AEGEAN). [Online] https://www.clinicaltrials.gov/ct2/show/NCT01884350 (accessed March 29 2015).
16. Lip GY,. My approach to the use of NOACs for stroke prevention in patients with atrial fibrillation. Trends Cardiovasc Med 2014; 24: 265-6.
17. NICE Implementation Collaborative. NICE NOAC Implementation Consensus Document: Supporting Local Implementation of NICE Guidance on the use of the Novel (non-Vitamin K Antagonist) Oral Anticoagulants in non-Valvular Atrial Fibrillation. London: National Institute of Health and Care Excellence, 2014.
18. Schulman S, Kearon C,; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
19. Beyer-Westendorf J, Förster K, Pannach S, et al., Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-62.
20. Patel MR, Mahaffey KW, Garg J, et al.,; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
21. Granger CB, Alexander JH, McMurray JJ, et al.,; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
22. Abraham NS, Singh S, Alexander GC, et al., Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857.